cGMPs and Compliance Resource Center
FDA final guidance detailing the types of actions, inaction, and circumstances that the FDA considers to constitute delaying, denying, or limiting inspection, or refusing to permit entry or inspection.
Significant factors contributing to uncertainty in the healthcare supply chain are more stringent regulations and increased product protection challenges
OEMs must comply with additional regulatory requirements
Pharma’s tech bench gets deeper with an All-Star lineup ready for the big leagues
White Papers: In Depth Research
Solutions Update: Quality, Compliance, Regulatory and Risk Management Solutions for the Increasingly Complex Pharmaceutical Industry
Posted: Sep 02, 2014
While market globalization has opened opportunities for pharmaceutical manufacturers, it has also intensified competition and the pressure to produce faster and at a lower cost.
Posted: Jul 30, 2014
Posted: Jul 29, 2014
Posted: Jul 14, 2014